Apnimed set to exit sleep disorder joint venture with Shionogi for $100M upfrontnews2026-03-24T11:19:25+00:00March 24th, 2026|Endpoints News|
Gilead bets $1.68B upfront on Ouro Medicines’ autoimmune program, with Galapagos expected to pitch innews2026-03-24T10:41:57+00:00March 24th, 2026|Endpoints News|
Merck partners with Flagship startup Quotient to search for genetic clues to IBDnews2026-03-24T10:00:17+00:00March 24th, 2026|Endpoints News|
